Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.

Antimicrobial Agents and Chemotherapy
José MoltóBonaventura Clotet

Abstract

The aim of this study was to evaluate the relationship between the virological response to darunavir-based salvage antiretroviral therapy and the darunavir genotypic and virtual inhibitory quotients (gIQ and vIQ, respectively). Thirty-seven HIV-infected patients failing protease inhibitor-based antiretroviral regimens who started salvage therapy containing darunavir-ritonavir were prospectively studied. The primary outcome of the study was a viral load (VL) of <50 copies/ml at week 48. The trough concentrations of darunavir in plasma, the number of darunavir resistance mutations, the change in the 50% inhibitory concentration (IC(50)) of darunavir in the virtual phenotype, and the darunavir gIQ and vIQ were correlated with the virological outcome in regression analyses adjusted by the number of active drugs in the background regimen. The VL was <50 copies/ml in 56.8% of patients at week 48. Changes in the VL were not significantly associated with the darunavir concentration (P = 0.304), the number of darunavir resistance mutations (P = 0.695), or the change in the IC(50) (P = 0.750). However, patients with darunavir vIQs of >or=1.5 had a 12-fold greater chance of achieving a >or=1 log(10) reduction in the VL (odds ratio [OR], 1...Continue Reading

References

Oct 20, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joseph GatheUNKNOWN RESIST-1 Study Group
Oct 20, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Pedro CahnDouglas Mayers
Jul 11, 2007·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Jean-Michel MolinaUNKNOWN TMC114-C215 Study Group
Oct 30, 2007·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Antonio D'AvolioGiovanni Di Perri
Dec 28, 2007·Antimicrobial Agents and Chemotherapy·Daniel Gonzalez de RequenaGiovanni Di Perri
Jun 14, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Martin S HirschDouglas D Richman

❮ Previous
Next ❯

Citations

Sep 12, 2012·Antimicrobial Agents and Chemotherapy·Edward P AcostaChristos J Petropoulos
Aug 27, 2009·Therapeutics and Clinical Risk Management·Michael Neely, Andrea Kovacs
Feb 8, 2011·Clinical Pharmacokinetics·Michael N Neely, Natella Y Rakhmanina
May 14, 2014·The Journal of Antimicrobial Chemotherapy·M Arab-AlameddineUNKNOWN Swiss HIV Cohort Study
Apr 12, 2014·The Journal of Antimicrobial Chemotherapy·Magali GarciaNicolas Venisse
Jan 26, 2010·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·C DelaugerreP de Truchis
Sep 15, 2016·Expert Review of Clinical Pharmacology·Baralee PunyawudhoKiat Ruxrungtham
Oct 22, 2014·International Journal of STD & AIDS·Lucia TaramassoUNKNOWN HIV/HCV Collaborative Liguria Group
Jun 3, 2021·AIDS·Jeremiah D MomperUNKNOWN IMPAACT P1026s Protocol Team

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Related Papers

Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
Constance DelaugerrePierre de Truchis
© 2022 Meta ULC. All rights reserved